Synthesis of 4-chloro-6-methoxy-2-methyl-3-nitroquinoline

被引：0

作者：

Zhao, Lei ^{[1
]}

Lei, Fei ^{[1
]}

Guo, Yuping ^{[1
]}

机构：

[1] Jiangxi Sci & Technol Normal Univ, Sch Pharm, Nanchang 330013, Jiangxi, Peoples R China

来源：

PROCEEDINGS OF THE 2016 7TH INTERNATIONAL CONFERENCE ON EDUCATION, MANAGEMENT, COMPUTER AND MEDICINE (EMCM 2016) | 2017年 / 59卷

关键词：

4-Chloro-6-methoxy-2-methyl-3-nitroquinoline; PI3K/mTOR inhibitor; Synthesis; INHIBITOR NVP-BEZ235; ANTITUMOR AGENTS; DERIVATIVES; CANCER;

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

4-Chloro-6-methoxy-2-methyl-3-nitroquinoline (1) was synthesized from 4-methoxyaniline through three steps including Cyclization, Nitrification and Chlorination. The structure of the target product (1) was confirmed by 1H NMR and MS. This method started with cheap raw materials was of simple experimental operation and mild reaction conditions. It was suitable for large scale pilot study and the yield of the product is achieved to 85%.

引用

页码：551 / 554

页数：4

共 13 条

[1] BASE INDUCED CYCLIZATION OF SOME QUINOLINES - FORMATION OF FUSED NITROGEN HETEROCYCLIC RING-SYSTEM [J].

ABBASI, MM ;

NASR, M ;

ZOOROB, HH .

MONATSHEFTE FUR CHEMIE, 1980, 111 (04) :963-969

[2] The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer [J].

Awasthi, Niranjan ;

Yen, Peter L. ;

Schwarz, Margaret A. ;

Schwarz, Roderich E. .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2012, 113 (03) :784-791

[3] Synthesis and biological activity of novel N-cycloalkyl-(cycloalkylaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides [J].

Berest, Galyna G. ;

Voskoboynik, Olexii Yu ;

Kovalenko, Sergiy I. ;

Antypenko, Olexii M. ;

Nosulenko, Inna S. ;

Katsev, Andrii M. ;

Shandrovskaya, Olena S. .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2011, 46 (12) :6066-6074

[4] CHEMOTHERAPEUTIC DYES .1. 5-ARALKYLAMINO-9-ALKYLAMINOBENZO[A]PHENOXAZINES [J].

CROSSLEY, ML ;

DREISBACH, PF ;

HOFMANN, CM ;

PARKER, RP .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1952, 74 (03) :573-578

[5] Targeting the PI3K-AKT-mTOR signaling network in cancer [J].

Khan, Khurum H. ;

Yap, Timothy A. ;

Yan, Li ;

Cunningham, David .

CHINESE JOURNAL OF CANCER, 2013, 32 (05) :253-265

[6] The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells [J].

Kim, Areumnuri ;

Park, Sunhoo ;

Lee, Jung-Eun ;

Jang, Won-Suk ;

Lee, Sun-Joo ;

Kang, Hye Jin ;

Lee, Seung-Sook .

LEUKEMIA RESEARCH, 2012, 36 (07) :912-920

[7] NVP-BEZ235 as a New Therapeutic Option for Sarcomas [J].

Manara, Maria C. ;

Nicoletti, Giordano ;

Zambelli, Diana ;

Ventura, Selena ;

Guerzoni, Clara ;

Landuzzi, Lorena ;

Lollini, Pier-Luigi ;

Maira, Saveur-Michel ;

Garcia-Echeverria, Carlos ;

Mercuri, Mario ;

Picci, Piero ;

Scotlandi, Katia .

CLINICAL CANCER RESEARCH, 2010, 16 (02) :530-540

[8] Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors [J].

Marone, Romina ;

Erhart, Dominik ;

Mertz, Ann C. ;

Bohnacker, Thomas ;

Schnell, Christian ;

Cmiljanovic, Vladimir ;

Stauffer, Frederic ;

Garcia-Echeverria, Carlos ;

Giese, Bernd ;

Maira, Sauveur-Michel ;

Wymann, Matthias P. .

MOLECULAR CANCER RESEARCH, 2009, 7 (04) :601-613

[9] SYNTHESIS OF BENZOXAZINOQUINOLINE AND NAPHTHOXAZINOQUINOLINE DERIVATIVES AS POSSIBLE ANTITUMOR AGENTS [J].

NASR, M ;

ABBASI, MM ;

NABIH, I .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1974, 63 (08) :1314-1316

[10] Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib [J].

Roulin, Didier ;

Waselle, Laurent ;

Dormond-Meuwly, Anne ;

Dufour, Marc ;

Demartines, Nicolas ;

Dormond, Olivier .

MOLECULAR CANCER, 2011, 10

← 1 2 →